Get the Stockscreener App
0.9917
1.81%
-0.0183
Barinthus Biotherapeutics Plc Adr stock is traded at $0.9917, with a volume of 7,838.
It is down -1.81% in the last 24 hours and down -0.33% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
See More
Previous Close:
$1.01
Open:
$1.01
24h Volume:
7,838
Relative Volume:
0.17
Market Cap:
$40.07M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-0.5165
EPS:
-1.92
Net Cash Flow:
$-56.34M
1W Performance:
+3.30%
1M Performance:
-0.33%
6M Performance:
-24.59%
1Y Performance:
-66.38%
1-Day Range:
$0.9917
$1.06
1-Week Range:
$0.945
$1.17
52-Week Range:
$0.8008
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.9917 | 40.07M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.62 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.38 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.64 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
Dollar General Corp (DG) Shares Up Despite Recent Market Volatility - The News Heater
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - MSN
Exclusive-Mexico's Pemex, billionaire Slim renegotiate deepwater gas project - Yahoo Finance
RBC raises Reckitt Benckiser stock target to £57.00, keeps outperform - MSN
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):